Ardelyx (NASDAQ:ARDX) Now Covered by TD Cowen

TD Cowen assumed coverage on shares of Ardelyx (NASDAQ:ARDX) in a research note published on Wednesday,Zacks reports. The brokerage issued a strong-buy rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on ARDX. Piper Sandler dropped their price objective on shares of Ardelyx from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Monday, August 17th. Wedbush reiterated an “outperform” rating and issued a $9.00 target price on shares of Ardelyx in a research note on Tuesday, August 18th. HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Ardelyx in a research report on Friday, August 7th. Zacks Research upgraded shares of Ardelyx from a “strong sell” rating to a “hold” rating in a research note on Friday, October 16th. Finally, BTIG Research dropped their price target on shares of Ardelyx from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.90.

Ardelyx Stock Performance

Shares of ARDX opened at $2.99 on Wednesday. Ardelyx has a 1 year low of $2.95 and a 1 year high of $8.40. The company has a debt-to-equity ratio of 1.54, a current ratio of 3.45 and a quick ratio of 3.15. The stock’s fifty day moving average price is $3.37 and its two-hundred day moving average price is $5.26. The firm has a market cap of $751.60 million, a PE ratio of -13.59 and a beta of 0.79.

Ardelyx (NASDAQ:ARDX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). Ardelyx had a negative return on equity of 35.30% and a negative net margin of 11.85%. The firm had revenue of $120.88 million for the quarter, compared to the consensus estimate of $121.03 million. During the same quarter in the previous year, the company posted ($0.08) EPS. The firm’s revenue was up 34.3% compared to the same quarter last year. On average, equities research analysts forecast that Ardelyx will post -0.20 EPS for the current year.

Insider Buying and Selling at Ardelyx

In other Ardelyx news, insider Mike Kelliher sold 7,758 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $29,945.88. Following the completion of the transaction, the insider owned 349,660 shares in the company, valued at $1,349,687.60. This trade represents a 2.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider James Brady sold 15,136 shares of Ardelyx stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total value of $58,424.96. Following the transaction, the insider directly owned 245,930 shares of the company’s stock, valued at $949,289.80. The trade was a 5.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 126,059 shares of company stock worth $486,588 in the last three months. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Ardelyx

A number of large investors have recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. purchased a new position in Ardelyx during the second quarter worth about $35,000. Sterling Capital Management LLC raised its holdings in shares of Ardelyx by 842.7% in the 3rd quarter. Sterling Capital Management LLC now owns 8,088 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 7,230 shares in the last quarter. SCS Capital Management LLC purchased a new stake in shares of Ardelyx in the 2nd quarter valued at about $52,000. ADAR1 Capital Management LLC purchased a new stake in shares of Ardelyx in the 2nd quarter valued at about $56,000. Finally, PVG Asset Management Corp bought a new stake in shares of Ardelyx during the 1st quarter valued at about $65,000. 58.92% of the stock is currently owned by institutional investors.

Key Headlines Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Ardelyx reported third-quarter EPS of $0.00, ahead of analysts’ expectation of a $0.02 loss. Product revenue was $125.5 million, while total revenue of $127.66 million came in slightly below estimates; revenue grew 21% year over year. The company maintained its 2026 IBSRELA revenue outlook of $350 million to $370 million. Ardelyx Q3 earnings
• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS estimate to $0.04 from $0.01 and its FY2026 estimate to a loss of $0.18 per share from a loss of $0.26. The firm kept its Buy rating and $13 price target. TD Cowen also reaffirmed its Buy rating. TD Cowen rating
• Neutral Sentiment: The company completed enrollment in its Phase 3 ACCEL trial of IBSRELA for adults with chronic idiopathic constipation, an operational milestone ahead of future trial updates. ACCEL trial enrollment
• Negative Sentiment: HC Wainwright cut its EPS forecasts for FY2027, FY2029 and FY2030, including a reduction for FY2029 to $1.18 from $1.56. The longer-term estimate revisions temper the improvement in its near-term outlook.
• Negative Sentiment: Multiple law firms publicized a securities class action against Ardelyx, with a November 16 lead-plaintiff deadline. The lawsuit alleges the company misrepresented payer access and reimbursement barriers affecting IBSRELA and XPHOZAH; these claims are allegations, not established findings. Litigation adds uncertainty and reputational risk. Class action allegations

Ardelyx Company Profile

Ardelyx, Inc is a biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal and cardiorenal diseases. The company’s platform is centered on regulating ion transport in the gut, with the goal of addressing conditions that are inadequately served by existing treatments.

Ardelyx’s marketed products include IBSRELA (tenapanor), an oral treatment for adults with irritable bowel syndrome with constipation, and XPHOZAH (tenapanor), a therapy designed to reduce serum phosphorus in adults with chronic kidney disease on dialysis who have an inadequate response to, or are intolerant of, phosphate binders.